Amarin's (NASDAQ:AMRN) share price took a hit this month after the Food and Drug Administration announced that it has still not decided whether the company's flagship drug, Vascepa, qualifies for New Chemical Entity, or NCE, status. Shares of Amarin are up today, however, on news that two new patents have been approved for Vascepa.

Although patents are an essential long-term shield against generic competition, will this really move the needle for Amarin's stock in the short term? Is NCE status still the biggest catalyst that investors need to watch?

In the following video, health care analysts Max Macaluso and Brenton Flynn discuss these issues.

Max Macaluso, Ph.D. and Brenton Flynn hold no positions in the stocks mentioned above. The Motley Fool owns shares of Dendreon and Abbott Laboratories. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.